FDA 503A and 503B compounding explained

FDA pharmacy compounding sits in an unusual middle zone between FDA-approved drugs and unregulated research chemicals. Compounded medications are made for individual patients (or for clinic supply) using bulk substances that don't have to go through the full FDA approval process — but they aren't entirely unregulated either. For strength peptides, compounding has been the closest thing to a legitimate prescription pathway, and understanding how 503A and 503B work explains why some peptides are accessible through US pharmacies and others aren't.

What compounding is

Compounding is the practice of a licensed pharmacist combining, mixing, or altering ingredients to create a medication tailored to an individual patient. It predates the FDA approval framework and exists to handle situations where a commercial drug doesn't fit a patient's needs — different dosage, allergy to an excipient, discontinued product, custom strength.

Modern federal compounding rules sit in two sections of the Federal Food, Drug, and Cosmetic Act:

• Section 503A — traditional pharmacy compounding for individual patients with prescriptions
• Section 503B — outsourcing facilities that compound in larger volumes for clinic supply

These were structured into law by the Drug Quality and Security Act of 2013, after a 2012 contamination event linked to a non-traditional compounder.

How 503A works

A 503A pharmacy is a state-licensed pharmacy that compounds for individual patients with valid prescriptions. Key features:

• Compounding requires a patient-specific prescription
• The pharmacy is regulated by the state board of pharmacy, with FDA oversight
• Bulk substances used must be either components of FDA-approved drugs or on the FDA 503A bulks list
• Quality requirements are pharmacy-grade
• Volume is limited; "office-use" compounding (clinic stocking without prescriptions) is restricted

503A is the route most clinicians and patients interact with. Peptide therapy clinics that can legally provide compounded peptides do so through 503A pharmacies (or in some cases 503B).

How 503B works

A 503B outsourcing facility is a different category created by the 2013 law. Key features:

• Federally registered with FDA, not just state-licensed
• Permitted to compound without patient-specific prescriptions, supplying clinics directly
• Subject to current Good Manufacturing Practices (cGMP) — closer to drug-manufacturer standards than to traditional pharmacy
• Larger production volumes
• A separate 503B bulks list applies

503B is the route by which clinics maintain stocking inventory of compounded peptides without each vial being tied to a specific patient script.

The bulks list framework

For both 503A and 503B, the substances used in compounding must satisfy one of these:

1. Be a component of an FDA-approved drug, or
2. Appear on the relevant bulks list (separate lists for 503A and 503B)

Substances are added to the bulks list through a nomination and review process. The FDA Pharmacy Compounding Advisory Committee (PCAC) reviews nominations and recommends inclusion or rejection. The FDA accepts or modifies those recommendations.

Criteria for inclusion include:

• Documented historical use
• Adequate safety data
• Defined therapeutic indications
• Reasonable manufacturing standardization

When any of these are insufficient, PCAC will recommend against inclusion.

Which strength peptides each pathway permits

Tesamorelin's compounding eligibility reflects its status as the active component of an FDA-approved drug. Sermorelin's reflects historical inclusion that has persisted across regulatory revisions.

The BPC-157 case study

The November 2023 FDA decision on BPC-157 is the most-cited recent compounding event. PCAC reviewed BPC-157 and recommended against inclusion on the 503A bulks list. The FDA accepted the recommendation. The cited concerns:

• Limited human safety data
• Unclear pharmacokinetics in humans
• Manufacturing standardization concerns
• No clearly-defined therapeutic indication

The decision did not declare BPC-157 unsafe. It declared the data insufficient to support pharmacy compounding. The practical consequence is that compounding pharmacies can no longer legally produce BPC-157, and patient access through prescription channels has effectively ended.

For more on what changed, see the news piece on the FDA decision.

What this means for clinicians and patients

A few practical implications:

• A clinician can prescribe Tesamorelin or compounded Sermorelin for appropriate indications, working with a 503A pharmacy
• A clinician cannot legally prescribe compounded BPC-157, TB-500, Ipamorelin, CJC-1295, IGF-1 LR3, or MOTS-c through US 503A pharmacies
• A clinic can stock compounded peptides via 503B for those substances that are on the 503B bulks list
• The peptides not on either list are accessible only as research chemicals

What might change

Future regulatory developments to watch:

• Additional 503A reviews of strength peptides not yet evaluated
• New nominations to the 503B bulks list
• State-level compounding rules that diverge from federal positions
• Industry IND (Investigational New Drug) applications, which would be the most legitimate path back to compounding eligibility for currently-excluded substances

The regulatory framework is not static. The 503A bulks list has been revised multiple times since the 2013 law, and additional reviews are expected.

Related reading

• Legal status of strength peptides in the US
• Choosing a peptide vendor
• Peptide purity explained
• International legal status of peptides